Cover Image
市場調查報告書

Opioids(類鴉片物質)誘發性便秘 - 開發平台分析

Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 257786
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
Opioids(類鴉片物質)誘發性便秘 - 開發平台分析 Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 63 Pages
簡介

Opioids(類鴉片物質)是有效的止痛藥,但偶而會有造成便秘的副作用。這些藥物皆會以各種形式影響消化器官。譬如由於Opioids(類鴉片物質)造成糞便在消化器官內移動速度減緩。在小腸中造成非推動性收縮,抑制了蠕動這個縱向推動力。結果造成食物在消化道中無法移動。Opioids(類鴉片物質)所造成的部分胃麻痺(胃不全麻痺)也會讓食物長期停留在消化器官中。不僅如此,Opioids(類鴉片物質)還會減少消化液的分泌,並抑制便意的產生。Opioids(類鴉片物質)誘發性便秘的症狀有感覺噁心、想吐、疲勞、無力、食欲不振等及心情低落。

本報告提供Opioids(類鴉片物質)誘發性便秘的治療藥開發平台現況及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,以及最新的新聞和發表等資料。

簡介

  • 調查範圍

Opioids(類鴉片物質)誘發性便秘 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品

企業開發中的產品

治療藥的開發企業

  • AstraZeneca PLC
  • Cosmo Pharmaceuticals S.p.A
  • Cubist Pharmaceuticals, Inc.
  • Develco Pharma Schweiz AG
  • Ironwood Pharmaceuticals, Inc.
  • S.L.A. Pharma AG
  • Salix Pharmaceuticals Ltd.
  • 鹽野義製藥
  • Sucampo Pharmaceuticals, Inc.
  • Synergy Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • axelopran
  • bevenopran
  • linaclotide
  • lubiprostone
  • methylnaltrexone bromide
  • naldemedine
  • naloxegol oxalate
  • naloxone hydrochloride
  • naloxone hydrochloride PR
  • naloxone hydrochloride SR
  • SP-333

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9574IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape.

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 2, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opioid-Induced Constipation (OIC) - Overview
    • Opioid-Induced Constipation (OIC) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Opioid-Induced Constipation (OIC) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
    • Develco Pharma Schweiz AG
    • Ironwood Pharmaceuticals Inc
    • Shionogi & Co Ltd
    • Sucampo Pharmaceuticals Inc
    • Synergy Pharmaceuticals Inc
    • Theravance Biopharma Inc
  • Opioid-Induced Constipation (OIC) - Drug Profiles
    • (axelopran sulfate + oxycodone hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axelopran sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dolcanatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linaclotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lubiprostone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • methylnaltrexone bromide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naldemedine tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride PR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Opioid-Induced Constipation (OIC) - Dormant Projects
  • Opioid-Induced Constipation (OIC) - Discontinued Products
  • Opioid-Induced Constipation (OIC) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan
      • Mar 23, 2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
      • Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of Naldemedine
      • Sep 07, 2016: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation
      • Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation
      • May 23, 2016: Two Naldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation
      • Mar 30, 2016: Shionogi Submits New Drug Applications In Japan And The U.S. For Naldemedine For The Treatment Of Opioid-Induced Constipation
      • Feb 19, 2016: Naldemedine Phase 3 Study Shows Significant Improvement for Patients with Opioid-Induced Constipation
      • Nov 30, 2015: Ironwood Reports Positive Top-Line Data from Phase II Trial of Linaclotide in Adult Patients With Opioid-Induced Constipation
      • Sep 10, 2015: Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek 2015
      • Aug 03, 2015: Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation
      • Jun 24, 2015: Shionogi Announces That Naldemedine Met The Primary Endpoint In Its First Japanese Phase 3 Study For The Treatment Of Opioid - Induced Constipation In Cancer Patients
      • May 19, 2015: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation
      • May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
      • Mar 30, 2015: Shionogi Announces That Naldemedine Mee1ts Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Pipeline by Theravance Biopharma Inc, H2 2017
  • Opioid-Induced Constipation (OIC) - Dormant Projects, H2 2017
  • Opioid-Induced Constipation (OIC) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Opioid-Induced Constipation (OIC), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top